Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML1657

Sigma-Aldrich

Gefitinib

≥98% (HPLC), powder, EGFR TK inhibitor

Sinonimo/i:

N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, ZD1839

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C22H24ClFN4O3
Numero CAS:
184475-35-2
Peso molecolare:
446.90
Numero MDL:
MFCD04307832
Codice UNSPSC:
12352200
ID PubChem:
329825996
NACRES:
NA.77

Nome del prodotto

Gefitinib, ≥98% (HPLC)

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 10 mg/mL, clear

Temperatura di conservazione

room temp

Stringa SMILE

COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4

InChI

1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
XGALLCVXEZPNRQ-UHFFFAOYSA-N

Informazioni sul gene

human ... EGFR(1956)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Gefitinib has been used :
  • To study its effective use in endometrial cancer therapy
  • Cell proliferation, cell cycle and apoptosis assays
  • Cell viability assay and colony formation assay

Azioni biochim/fisiol

Gefitinib is a selective epidermal growth factor receptor tyrosine kinase (EGFR TK) inhibitor. Gefitinib has antineoplastic activity, and has been approved for the treatment on non-small cell lung cancer (NSCLC).
Gefitinib has a higher affinity for ATP (adenosine triphosphate) binding site in the EGFR tyrosine kinase domain than ATP. Hence, gefitinib is known to inhibit the progression of endometrial cancer.

Avvertenze

Danger

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
076M4739V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

PD153035 hydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML0564

PD153035 hydrochloride

Imatinib mesylate ≥98% (HPLC)

Sigma-Aldrich

SML1027

Imatinib mesylate

EGFR Inhibitor The EGFR Inhibitor, also referenced under CAS 879127-07-8, controls the biological activity of EGFR. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Sigma-Aldrich

324674

EGFR Inhibitor

Nelarabine ≥98% (HPLC)

Sigma-Aldrich

SML1736

Nelarabine

Imatinib

Sigma-Aldrich

CDS022173

Imatinib

Nilotinib

Sigma-Aldrich

CDS023093

Nilotinib

The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma.
Qiu M, et al.
Cancer Research, 78(11), 2839-2851 (2018)
Roy S Herbst et al.
The oncologist, 7 Suppl 4, 9-15 (2002-08-31)
Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less
Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.
Yang Y, et al.
Oncotarget, 8(70), 115360-115360 (2017)
Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a.
Fu Y, et al.
Frontiers in Pharmacology, 9, 82-82 (2018)
P M Ellis et al.
Current oncology (Toronto, Ont.), 22(3), e183-e215 (2015-06-20)
This systematic review addresses the use of epidermal growth factor receptor (egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients-unselected, selected, and molecularly selected-in three treatment settings: first line, second line, and maintenance. Ninety-six randomized controlled trials
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.